If patients with SG who show greater remission of MASLD also exhibit a larger reduction in adipose PRTN3 levels, it may indicate a mechanistic link between adipose immune signaling and hepatic outcomes. Here, PRTN3 is linked to metabolic dysfunction-associated steatotic liver disease.